Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 9/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.35 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.34 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.34 |
| ▸ | WNT1 | P04628 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25588520 | 1.00 | PTPN1 (0.46) | PTPN1PTPN2ACLYAURKATTK | |
| SCHEMBL2930306 | 0.82 | PTPN1 (0.58) | PTPN1PTPN2AURKATTKAURKB | |
| SCHEMBL2933879 | 0.79 | PTPN1 (0.59) | PTPN1PTPN2 | |
| SCHEMBL25587786 | 0.75 | PTPN2 (0.49) | PTPN1PTPN2 | |
| SCHEMBL25206843 | 0.75 | PTPN2 (0.40) | PTPN1PTPN2SMARCA2SMARCA4WNT1 | |
| SCHEMBL3213434 | 0.72 | PTPN1 (0.48) | PTPN1PTPN2 | |
| SCHEMBL2936369 | 0.71 | PTPN1 (0.50) | PTPN1PTPN2 | |
| SCHEMBL3201397 | 0.70 | PTPN1 (0.53) | PTPN1PTPN2AURKBDYRK1A | |
| SCHEMBL3213594 | 0.70 | PTPN1 (0.53) | PTPN1PTPN2AURKBDYRK1A | |
| SCHEMBL2937214 | 0.70 | PTPN1 (0.64) | PTPN1PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240398828-A1 | HETERO-ATOM CONTAINING COMPOUNDS AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2024-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240398828-A1 | HETERO-ATOM CONTAINING COMPOUNDS AND USES THEREOF | CD74, HLA-DRB1, CD47 | PTPN1 776/4885PTPN2 478/4885ACLY 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.